REGENXBIO Inc. has announced a strategic royalty monetization agreement with Healthcare Royalty (HCRx) valued at up to $250 million. The agreement involves a non-dilutive, limited recourse royalty bond, allowing REGENXBIO to monetize select anticipated royalties and milestones. The company received an immediate $150 million at closing, extending its cash runway into early 2027. This financing will support REGENXBIO's commercial preparations and late-stage activities, while also retaining potential future non-dilutive funding opportunities. The deal underlines REGENXBIO's position as a leader in rare and retinal gene therapies, aiming to unlock significant value for shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.